Tweets
Review of Amyloidosis
The New England Journal of Medicine has published a review of systemic amyloidosis.
https://t.co/qtbdPrlKnj https://t.co/wcqvRAauWC
Dr. John Cush @RheumNow ( View Tweet )
1 year 10 months ago
Predicting Palindromic Prognosis
Dr. David Liew discusses abstract OP0127, "PREDICTING PERSISTENT INFLAMMATORY ARTHRITIS IN PATIENTS WITH PALINDROMIC RHEUMATISM: DEVELOPMENT OF SCORES FOR RISK STRATIFICATION", at Eular 2024 in Vienna, Austria.
https://t.co/Yzr9feNjjF https://t.co/BKVbDv3e4E
Dr. John Cush @RheumNow ( View Tweet )
1 year 10 months ago
ICYMI: Enthesitis, Synovitis, and Tenosynovitis in Psoriatic Arthritis
An ultrasound study suggests that enthesitis is associated with both synovitis and tenosynovitis in patients with Psoriatic arthritis (PsA)
https://t.co/JjhkQM672t. https://t.co/dM25kIcC26
Dr. John Cush @RheumNow ( View Tweet )
1 year 10 months ago
RT @drdavidliew I have to say: upadacitinib looks very decent for GCA. Not a panacea, but it definitely does something & good safety during trial.
Would love to eventually see:
- H2H comparative effect vs toci, secukinumab
- structural outcomes
- long-term safety
#EULAR2024
Dr. John Cush @RheumNow ( View Tweet )
1 year 10 months ago
RT @yuz6yusof
#EULAR2024 OP0180 Can we safely taper GC in #lupus patients who are in remission? Single study in Italy showed in pts with SLEDAI=0 + pred =<5mg/d + stable IS/HCQ, GC discontinuation after proper tapering appeared safe and was associated with a low risk of flare
Dr. John Cush @RheumNow ( View Tweet )
1 year 10 months ago
10 baseline predictors for achieving treatment response to Secukinumab in the EuroSpA study. Having non-radiographic disease was a negative predictor of obtaining LDA at 6 months and remaining on treatment at 12 months in European axSpA patients initiating secukinumab.
#EULAR2024
Dr. John Cush @RheumNow ( View Tweet )
1 year 10 months ago
Review of Amyloidosis
The New England Journal of Medicine has published a review of systemic amyloidosis.
https://t.co/4507N4DwLk https://t.co/Q0MP5XXUHr
Dr. John Cush @RheumNow ( View Tweet )
1 year 10 months ago
Future Big BiTEs (6.28.2024)
Dr. Jack Cush reviews the news, journal articles and regulatory announcements from the past week on https://t.co/V10S4oVFsv.
https://t.co/AKb2qmQ2nf https://t.co/3nKuEXteXS
Dr. John Cush @RheumNow ( View Tweet )
1 year 10 months ago
RT @drminidey
OP0165- incidence & risk factors of D2T RA in an early RA cohort
Factors assoc with D2T RA:
🩸 Seropositivity
🦴 Erosions
📈 Disease activity
📊 D2T pts have higher steroid doses & more commonly develop iatrogenic-related #comorbidities, e.g. osteoporosis
Dr. John Cush @RheumNow ( View Tweet )
1 year 10 months ago
FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US. The US FDA has also approved 2 other biosimilars to ustekinumab, including ustekinumab-aekn (Selarsdi) and ustekinumab-auub (Wezlana). https://t.co/BgYQm39aEB https://t.co/XZhnHxPaP0
Links:
Dr. John Cush @RheumNow ( View Tweet )
1 year 10 months ago
How do you manage new progressive ILD?
Dr. John Cush @RheumNow ( View Tweet )
1 year 10 months ago
RT @drdavidliew
"We’ve got better at treating RA over the last 20 years, and it’s genuinely saving lives.
Something to be very proud of. Let’s not forget that!
5y mortality from DANBIO
(still, we still have work to do in seropos RA in men!)
#EULAR2024 OP0162
Dr. John Cush @RheumNow ( View Tweet )
1 year 10 months ago
